| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Fernando G Romeiro | Q79258968 |
| P2093 | author name string | Lívia Alves Amaral Santos | |
| P2860 | cites work | Calcium Supplements and Cardiovascular Disease: A Review | Q22299228 |
| Glucocorticosteroids for primary biliary cirrhosis | Q24244255 | ||
| Group based training for self-management strategies in people with type 2 diabetes mellitus | Q24246904 | ||
| Guidelines on the management of osteoporosis associated with chronic liver disease | Q24685899 | ||
| Calcium and Vitamin D Supplementations: 2015 Position Statement of the Korean Society for Bone and Mineral Research | Q26771717 | ||
| Calcium intake and risk of fracture: systematic review | Q26784357 | ||
| Alcoholic liver disease and changes in bone mineral density | Q26822573 | ||
| Hepatic osteodystrophy | Q27004571 | ||
| Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | Q27860743 | ||
| Decreased bone density, elevated serum osteoprotegerin, and beta-cross-laps in Wilson disease | Q31117495 | ||
| Vitamin K and the prevention of fractures: systematic review and meta-analysis of randomized controlled trials | Q33248007 | ||
| Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications | Q33953964 | ||
| Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice | Q34223451 | ||
| Review article: the extra-skeletal effects of vitamin D in chronic hepatitis C infection | Q34252987 | ||
| The RANKL/OPG system and bone mineral density in patients with chronic liver disease. | Q53658379 | ||
| Randomized pilot trial of vitamin K2 for bone loss in patients with primary biliary cirrhosis. | Q55035486 | ||
| EASL Clinical Practice Guidelines: management of cholestatic liver diseases. | Q55051951 | ||
| Prophylactic Bisphosphonate Treatment Prevents Bone Fractures After Liver Transplantation | Q57168211 | ||
| Longitudinal study on osteodystrophy in primary biliary cirrhosis (PBC) and a pilot study on calcitonin treatment | Q57226640 | ||
| Osteoporosis in Primary Biliary Cirrhosis: A Randomized Trial of the Efficacy and Feasibility of Estrogen/Progestin | Q58311495 | ||
| Fracture Risk in People With Primary Biliary Cirrhosis: A Population-Based Cohort Study | Q58376321 | ||
| Observation ofe+e−→π0π0hcand a Neutral Charmoniumlike StructureZc(4020)0 | Q58448986 | ||
| Mineral metabolism, osteoblastic function and bone mass in chronic alcoholism | Q58868283 | ||
| Low testosterone levels as an independent predictor of mortality in men with chronic liver disease | Q62978474 | ||
| Sodium fluoride prevents bone loss in primary biliary cirrhosis | Q67590482 | ||
| Reduced spinal and femoral bone mass and deranged bone mineral metabolism in chronic alcoholics | Q67821217 | ||
| Factors influencing the development of metabolic bone disease in primary biliary cirrhosis | Q68573003 | ||
| Bone mass in women with primary biliary cirrhosis: the relation with histological stage and use of glucocorticoids | Q68903834 | ||
| Hepatic osteodystrophy. Static and dynamic bone histomorphometry and serum bone Gla-protein in 80 patients with chronic liver disease | Q69734919 | ||
| Osteoporosis in hemochromatosis: iron excess, gonadal deficiency, or other factors? | Q69951457 | ||
| Hypogonadism in hemochromatosis: reversal with iron depletion | Q70500617 | ||
| A prospective survey of radiological bone and joint changes in primary biliary cirrhosis | Q70791205 | ||
| Serum IGF 1 is low and correlated with osteoblastic surface in idiopathic osteoporosis | Q70961601 | ||
| Bone disease in primary biliary cirrhosis: increased bone resorption and turnover in the absence of osteoporosis or osteomalacia | Q71259493 | ||
| Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI | Q71728011 | ||
| Inappropriately low levels of gonadotrophins in amenorrhoeic women with alcoholic and non-alcoholic cirrhosis | Q72144895 | ||
| Parenteral calcitonin for metabolic bone disease associated with primary biliary cirrhosis | Q72164989 | ||
| Bone mass improves in alcoholics after 2 years of abstinence | Q72400233 | ||
| Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment | Q72688424 | ||
| High serum osteoprotegerin and low RANKL in primary biliary cirrhosis | Q73187923 | ||
| Collagen type Ialpha1 gene polymorphism in idiopathic osteoporosis in men | Q73208639 | ||
| Glucocorticoid-induced osteoporosis | Q73280028 | ||
| Osteopenia assessed by body composition analysis is related to malnutrition in alcoholic patients | Q73406314 | ||
| Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: preliminary results after 2 years | Q73475924 | ||
| Plasma vitamin K1 level is decreased in primary biliary cirrhosis | Q73856374 | ||
| Long-term persistence of low bone density in orthotopic liver transplantation | Q74060632 | ||
| Bone metabolism in advanced cholestatic liver disease: analysis by bone histomorphometry | Q77150135 | ||
| Estrogen-progestogen therapy for low bone mineral density in primary biliary cirrhosis | Q77965311 | ||
| Experimental cholestatic liver disease through bile-duct ligation in rats results in skeletal fragility and impaired osteoblastogenesis | Q80042381 | ||
| Insulin-like growth factor I gene microsatellite repeat, collagen type Ialpha1 gene Sp1 polymorphism, and bone disease in primary biliary cirrhosis | Q80347072 | ||
| Bone mineral density in men with genetic hemochromatosis and HFE gene mutation | Q81803540 | ||
| Prognosis of osteopenia in chronic alcoholics | Q82313063 | ||
| Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation | Q82894553 | ||
| Patients with cirrhosis and ascites have false values of bone density: implications for the diagnosis of osteoporosis | Q84855420 | ||
| Efficacy of different therapeutic regimens on hepatic osteodystrophy in chronic viral liver disease | Q85041219 | ||
| Handgrip strength as a predictor of bone mineral density in outpatients with cirrhosis | Q85652202 | ||
| Glucocorticoid-induced Osteoporosis | Q86816040 | ||
| Association between nutritional screening via the Controlling Nutritional Status index and bone mineral density in chronic liver disease of various etiologies | Q87439840 | ||
| Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis. | Q50480283 | ||
| A 3-year pilot study with 1,25-dihydroxyvitamin D, calcium, and calcitonin for severe osteodystrophy in primary biliary cirrhosis. | Q50623946 | ||
| Calcitriol for bone disease in patients with cirrhosis of the liver. | Q50648822 | ||
| Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. | Q50684179 | ||
| Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation. | Q50868269 | ||
| Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation. | Q50970251 | ||
| Calcitonin and bisphosphonates treatment in bone loss after liver transplantation | Q51587311 | ||
| Ethanol reduces bone formation and may cause osteoporosis. | Q51755941 | ||
| Hyperbilirubinemia is not a major contributing factor to altered bone mineral density in patients with chronic liver disease. | Q51802919 | ||
| Postmenopausal osteoporosis - clinical, biological and histopathological aspects. | Q53611560 | ||
| Clinical, biochemical, and histological studies of osteomalacia, osteoporosis, and parathyroid function in chronic liver disease | Q34473833 | ||
| Erythromycin versus neomycin in the treatment of hepatic encephalopathy in cirrhosis: a randomized double-blind study | Q34550014 | ||
| Treatment of bone loss in patients with chronic liver disease awaiting liver transplantation | Q34570115 | ||
| The structural and biomechanical basis of the gain and loss of bone strength in women and men. | Q35108965 | ||
| Osteoporosis in liver diseases and after liver transplantation | Q35134421 | ||
| AGA technical review on osteoporosis in hepatic disorders. | Q35209520 | ||
| The risks and benefits of calcium supplementation | Q35260948 | ||
| The risk of osteoporosis in patients with liver cirrhosis: a meta-analysis of literature studies | Q35589088 | ||
| Hepatic osteodystrophy: An important matter for consideration in chronic liver disease. | Q35635642 | ||
| Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density | Q35674916 | ||
| Spinal Orthoses for Vertebral Osteoporosis and Osteoporotic Vertebral Fracture: A Systematic Review | Q35854985 | ||
| Osteoporosis: a still increasing prevalence | Q36385297 | ||
| Treatment of bone disorders in liver disease | Q36537610 | ||
| Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures | Q36598613 | ||
| Prospective study of profile of hepatic osteodystrophy in patients with non-choleastatic liver cirrhosis and impact of bisphosphonate supplementation | Q36616083 | ||
| Vitamin D replacement for cirrhosis-related bone disease | Q36666317 | ||
| Bone loss after orthotopic liver transplantation | Q36728610 | ||
| Chronic alcohol ingestion induces osteoclastogenesis and bone loss through IL-6 in mice | Q37270933 | ||
| Bone mineral density and disorders of mineral metabolism in chronic liver disease | Q37275718 | ||
| Cholestasis and metabolic bone disease - a clinical review | Q37322123 | ||
| Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone | Q37383855 | ||
| Current understanding of osteoporosis associated with liver disease | Q37625814 | ||
| Liver and bone. | Q37764169 | ||
| The role of intestinal endotoxin in liver injury: A long and evolving history | Q37796722 | ||
| Metabolic bone disease in primary biliary cirrhosis | Q37804832 | ||
| Bone Disorders in Chronic Liver Diseases | Q37811999 | ||
| Management of osteoporosis in liver disease. | Q37872491 | ||
| Testosterone in men with advanced liver disease: abnormalities and implications | Q38236451 | ||
| Vitamin D status, bone metabolism and bone mass in patients with alcoholic liver cirrhosis | Q38432992 | ||
| Bone disorders in patients with chronic liver disease awaiting liver transplantation. | Q38484693 | ||
| Effect of ascites on bone density measurement in cirrhosis | Q38504768 | ||
| Vertebral Fractures: Clinical Importance and Management | Q38622503 | ||
| Bone changes in alcoholic liver cirrhosis. A histomorphometrical analysis of 52 cases | Q39518231 | ||
| Excess iron inhibits osteoblast metabolism | Q39802555 | ||
| Soluble RANKL and risk of nontraumatic fracture | Q40527958 | ||
| Osteoporosis in chronic liver disease: pathogenesis, risk factors, and management | Q40589823 | ||
| Vitamin K2 and geranylgeraniol, its side chain component, inhibited osteoclast formation in a different manner | Q40600776 | ||
| Sodium fluoride therapy of postmenopausal osteoporosis | Q40820036 | ||
| Prevalence of hepatic osteodystrophy and vitamin D deficiency in cirrhosis | Q41509953 | ||
| Protective effect of Korean Red Ginseng against glucocorticoid-induced osteoporosis in vitro and in vivo | Q41655841 | ||
| Lithocholic acid downregulates vitamin D effects in human osteoblasts | Q43200287 | ||
| Health-related quality of life after liver transplantation for adult recipients | Q43252008 | ||
| Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis. | Q43466373 | ||
| Prevalence and characteristics of bone disease in cirrhotic patients under evaluation for liver transplantation. | Q43511328 | ||
| Transdermal estrogen therapy improves lipid profile and osteoporosis in postmenopausal liver transplant patients | Q43553066 | ||
| Effects of testosterone and venesection on spinal and peripheral bone mineral in six hypogonadal men with hemochromatosis | Q43589038 | ||
| Alcoholic cirrhosis and osteoporosis in men: a light and scanning electron microscopy study. | Q43988263 | ||
| Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. | Q44025886 | ||
| Effects of a single infusion of pamidronate prior to liver transplantation: a bone histomorphometric study | Q44033835 | ||
| Lack of effect of intravenous pamidronate on fracture incidence and bone mineral density after orthotopic liver transplantation. | Q44036839 | ||
| Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation | Q44309060 | ||
| Vitamin K stimulates osteoblastogenesis and inhibits osteoclastogenesis in human bone marrow cell culture | Q44358332 | ||
| Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis | Q44627887 | ||
| Transdermal hormone replacement therapy improves vertebral bone density in primary biliary cirrhosis: results of a 1-year controlled trial. | Q44778662 | ||
| An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis | Q44930771 | ||
| Osteoporosis, mineral metabolism, and serum soluble tumor necrosis factor receptor p55 in viral cirrhosis | Q45050559 | ||
| Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study | Q45255372 | ||
| Low bone mineral density and impaired bone metabolism in young alcoholic patients without liver cirrhosis: a cross-sectional study. | Q46215836 | ||
| Short-term effects of high-dose zoledronic acid treatment on bone mineralization density distribution after orthotopic liver transplantation | Q46276736 | ||
| Pamidronate and osteoporosis prevention in liver transplant recipients | Q46281211 | ||
| Primary biliary cirrhosis and osteoporosis: a case-control study | Q46351576 | ||
| Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial | Q46364237 | ||
| Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study | Q46611597 | ||
| Prevalence of vitamin D deficiency in chronic liver disease | Q46631954 | ||
| Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial | Q46714065 | ||
| Evaluation of adherence to treatment with calcium and vitamin D in the elderly in a basic health area | Q50241490 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | liver cirrhosis | Q147778 |
| osteoporosis | Q165328 | ||
| dietary supplement | Q645858 | ||
| organic compound, having C-P covalent bound | Q2182492 | ||
| hormone replacement therapy | Q3354346 | ||
| physiological phenomenon | Q66615932 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 1423462 | |
| P577 | publication date | 2016-01-01 | |
| 2016-10-20 | |||
| P1433 | published in | BioMed Research International | Q17509958 |
| P1476 | title | Diagnosis and Management of Cirrhosis-Related Osteoporosis | |
| P478 | volume | 2016 |
| Q55333063 | Adefovir dipivoxil induced hypophosphatemic osteomalacia in chronic hepatitis B: a comparative study of Chinese and foreign case series. |
| Q47706915 | Anti-arthritic activity of cell wall content of Lactobacillus plantarum in freund's adjuvant-induced arthritic rats: involvement of cellular inflammatory mediators and other biomarkers |
| Q93079405 | Bone Diseases in Patients with Chronic Liver Disease |
| Q92263169 | Comparative assessment of sarcopenia using the JSH, AWGS, and EWGSOP2 criteria and the relationship between sarcopenia, osteoporosis, and osteosarcopenia in patients with liver cirrhosis |
| Q99578630 | Effects of denosumab treatment in chronic liver disease patients with osteoporosis |
| Q58707401 | Hyponatremia and the risk of kidney stones: A matched case-control study in a large U.S. health system |
| Q55100672 | Increased risk of osteoporosis in patients with primary biliary cirrhosis. |
| Q91934303 | Safety and efficacy of risedronate for patients with esophageal varices and liver cirrhosis: a non-randomized clinical trial |
| Q47437950 | Second Hip Fracture: Incidence, Trends, and Predictors |
Search more.